New drug aims to halt silent kidney damage

NCT ID NCT06797518

Summary

This study is testing whether adding an investigational oral drug called iptacopan to standard supportive care can reduce harmful immune activity and slow kidney damage in adults with IgA nephropathy. Researchers will compare kidney biopsies from 20 participants before and after 9 months of treatment to look for changes in specific markers of disease. The goal is to see if the drug helps control the underlying disease process.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNOGLOBULIN A NEPHROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-••••

Locations

  • CaRe Research

    RECRUITING

    Chubbuck, Idaho, 83202, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Central Florida Kidney Specialists

    RECRUITING

    Orlando, Florida, 32806, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • DaVita Clinical Research

    RECRUITING

    Las Vegas, Nevada, 89146, United States

    Contact Email: •••••@•••••

    Contact

  • Georgia Nephrology Research Inst

    RECRUITING

    Lawrenceville, Georgia, 30046, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Novartis Investigative Site

    RECRUITING

    CABA, Buenos Aires, 1280, Argentina

  • Novartis Investigative Site

    RECRUITING

    CABA, Buenos Aires, 1425, Argentina

  • Novartis Investigative Site

    RECRUITING

    Ashdod, 7747629, Israel

  • Novartis Investigative Site

    RECRUITING

    Hadera, 3820302, Israel

  • Novartis Investigative Site

    RECRUITING

    Haifa, 3109601, Israel

  • Novartis Investigative Site

    RECRUITING

    Nahariya, 2210001, Israel

  • Novartis Investigative Site

    RECRUITING

    Kuala Lumpur, Selangor, 43000, Malaysia

  • OSU Wexner Medical Center

    RECRUITING

    Columbus, Ohio, 43210, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Prolato Clinical Research Center

    RECRUITING

    Houston, Texas, 77054, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • UCLA Medical Center

    RECRUITING

    Los Angeles, California, 90095, United States

    Contact Email: •••••@•••••

    Contact

  • University Hospitals Cleveland Medical Center

    RECRUITING

    Cleveland, Ohio, 44106, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Alabama at Birmingham

    RECRUITING

    Birmingham, Alabama, 35294, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.